Ageing is a risk factor in imatinib mesylate cardiotoxicity

The role of mitochondria in aging

(2013) Ana Bratic et al.   JOURNAL OF CLINICAL INVESTIGATION

Signaling effectors underlying pathologic growth and remodeling of the heart

(2013) Jop H. van Berlo et al.   JOURNAL OF CLINICAL INVESTIGATION

Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors

(2012) Richard M. Steingart et al.   AMERICAN HEART JOURNAL

Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: Results of the AFR04 study

(2012) Philippe Rousselot et al.   AMERICAN JOURNAL OF HEMATOLOGY

Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer

(2012) C Nabhan et al.   BRITISH JOURNAL OF CANCER

Cancer drugs and the heart: importance and management

(2012) T. M. Suter et al.   EUROPEAN HEART JOURNAL

BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases

(2012) Zsolt Sarszegi et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Dissociation of Cardiogenic and Postnatal Myocardial Activities of GATA4

(2012) J. M. Gallagher et al.   MOLECULAR AND CELLULAR BIOLOGY

Mechanistic Investigation of Imatinib-Induced Cardiac Toxicity and the Involvement of c-Abl Kinase

(2012) Wenyue Hu et al.   TOXICOLOGICAL SCIENCES

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

(2011) H. M. Kantarjian et al.   BLOOD

Fatal Heart Failure After a 26-Month Combination of Tyrosine Kinase Inhibitors in a Papillary Thyroid Cancer

(2011) Marie-Elisabeth Toubert et al.   THYROID

A Multifaceted Evaluation of Imatinib-induced Cardiotoxicity in the Rat

(2011) Eugene H. Herman et al.   TOXICOLOGIC PATHOLOGY

Cell Death in the Pathogenesis of Heart Disease: Mechanisms and Significance

(2010) Russell S. Whelan et al.   Annual Review of Physiology

Cardiac Natriuretic Peptides: From Basic Discovery to Clinical Practice

(2010) Salim Hayek et al.   Cardiovascular Therapeutics

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology

(2010) Thomas Eschenhagen et al.   EUROPEAN JOURNAL OF HEART FAILURE

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial

(2010) Axel Le Cesne et al.   LANCET ONCOLOGY

Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies

(2010) Armin Wolf et al.   LEUKEMIA RESEARCH

RelB-Dependent Differential Radiosensitization Effect of STI571 on Prostate Cancer Cells

(2010) Yong Xu et al.   MOLECULAR CANCER THERAPEUTICS

Cardiotoxicity of anticancer treatments: what the cardiologist needs to know

(2010) Michael S. Ewer et al.   Nature Reviews Cardiology

Congestive heart failure during imatinib mesylate treatment

(2009) Gina Turrisi et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

The mitochondrial death pathway: a promising therapeutic target in diseases

(2009) Sanjeev Gupta et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE